Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion

Objective: to evaluate efficacy and safety of intravitreal injections of bevacizumab in the treatment of macular edema secondary to retinal vein occlusion (RVO). Methods: prospective study, noncomparative, interventional case series. Twelve consecutive patients (12 eyes) with macular edema associate...

ver descrição completa

Detalhes bibliográficos
Autores: Mesa Gutiérrez, Juan Carlos, Arias Barquet, Lluís, Caminal Mitjana, Josep Maria, Prades Almolda, Sergi, Planas, Núria, Pujol Goita, Octavi, Rubio Caso, Marc, Arruga Ginebreda, Jordi
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2008
País:España
Recursos:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/173625
Acesso em linha:https://hdl.handle.net/2445/173625
Access Level:acceso abierto
Palavra-chave:Malalties de la retina
Factor de creixement de l'endoteli vascular
Edema
Retinal diseases
Vascular endothelial growth factors
id ES_c8af6eb6cb38b1e2c536c87b70b2ea8c
oai_identifier_str oai:recercat.cat:2445/173625
network_acronym_str ES
network_name_str España
repository_id_str
spelling Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusionMesa Gutiérrez, Juan CarlosArias Barquet, LluísCaminal Mitjana, Josep MariaPrades Almolda, SergiPlanas, NúriaPujol Goita, OctaviRubio Caso, MarcArruga Ginebreda, JordiMalalties de la retinaFactor de creixement de l'endoteli vascularEdemaRetinal diseasesVascular endothelial growth factorsEdemaObjective: to evaluate efficacy and safety of intravitreal injections of bevacizumab in the treatment of macular edema secondary to retinal vein occlusion (RVO). Methods: prospective study, noncomparative, interventional case series. Twelve consecutive patients (12 eyes) with macular edema associated with nonischemic retinal vein occlusion were treated with intravitreal bevacizumab (1.25 mg). All subjects underwent standardized ophthalmic evaluation at baseline and at weeks 1, 4, 12, and 24, consisting of visual acuity (VA) measurement using ETDRS charts, and imaging with ocular coherence tomography evaluating changes in foveal thickness (FT) and macular volume (MV). Results: the median age was 66 years (± 4.16), and the median duration of symptoms was 4 months (± 1.81). There were six cases of inferior branch vein occlusion and six cases of superior branch retinal vein occlusion. Mean VA improved from 1.32 ± 0.24 (logMAR values) at baseline to 0.8 ± 0.15 (p = 0.0003) at the 6-month follow-up. The macular edema responded promptly, and a trend to restoration of normal macular anatomy was observed at by the seventh day. Mean FT improved from 615.50 ± 116.29 microns to 420 ± 72.53 microns (p = 0.001), and the mean MV improved from 19.81 ± 2.31mm3 to 9.23 ± 1.38 (p = 0.0001) at the 6-month follow-up.Dove Medical Press2021202120082021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion5 p.application/pdfhttps://hdl.handle.net/2445/173625Articles publicats en revistes (Ciències Clíniques)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.2147/opth.s3798Clinical Ophthalmology, 2008, vol. 2, num. 4, p. 787-791https://doi.org/10.2147/opth.s3798cc-by-nc (c) Mesa Gutiérrez, Juan Carlos et al., 2008http://creativecommons.org/licenses/by-nc/3.0/esinfo:eu-repo/semantics/openAccessoai:recercat.cat:2445/1736252026-05-29T05:05:01Z
dc.title.none.fl_str_mv Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
title Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
spellingShingle Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
Mesa Gutiérrez, Juan Carlos
Malalties de la retina
Factor de creixement de l'endoteli vascular
Edema
Retinal diseases
Vascular endothelial growth factors
Edema
title_short Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
title_full Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
title_fullStr Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
title_full_unstemmed Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
title_sort Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
dc.creator.none.fl_str_mv Mesa Gutiérrez, Juan Carlos
Arias Barquet, Lluís
Caminal Mitjana, Josep Maria
Prades Almolda, Sergi
Planas, Núria
Pujol Goita, Octavi
Rubio Caso, Marc
Arruga Ginebreda, Jordi
author Mesa Gutiérrez, Juan Carlos
author_facet Mesa Gutiérrez, Juan Carlos
Arias Barquet, Lluís
Caminal Mitjana, Josep Maria
Prades Almolda, Sergi
Planas, Núria
Pujol Goita, Octavi
Rubio Caso, Marc
Arruga Ginebreda, Jordi
author_role author
author2 Arias Barquet, Lluís
Caminal Mitjana, Josep Maria
Prades Almolda, Sergi
Planas, Núria
Pujol Goita, Octavi
Rubio Caso, Marc
Arruga Ginebreda, Jordi
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Malalties de la retina
Factor de creixement de l'endoteli vascular
Edema
Retinal diseases
Vascular endothelial growth factors
Edema
topic Malalties de la retina
Factor de creixement de l'endoteli vascular
Edema
Retinal diseases
Vascular endothelial growth factors
Edema
description Objective: to evaluate efficacy and safety of intravitreal injections of bevacizumab in the treatment of macular edema secondary to retinal vein occlusion (RVO). Methods: prospective study, noncomparative, interventional case series. Twelve consecutive patients (12 eyes) with macular edema associated with nonischemic retinal vein occlusion were treated with intravitreal bevacizumab (1.25 mg). All subjects underwent standardized ophthalmic evaluation at baseline and at weeks 1, 4, 12, and 24, consisting of visual acuity (VA) measurement using ETDRS charts, and imaging with ocular coherence tomography evaluating changes in foveal thickness (FT) and macular volume (MV). Results: the median age was 66 years (± 4.16), and the median duration of symptoms was 4 months (± 1.81). There were six cases of inferior branch vein occlusion and six cases of superior branch retinal vein occlusion. Mean VA improved from 1.32 ± 0.24 (logMAR values) at baseline to 0.8 ± 0.15 (p = 0.0003) at the 6-month follow-up. The macular edema responded promptly, and a trend to restoration of normal macular anatomy was observed at by the seventh day. Mean FT improved from 615.50 ± 116.29 microns to 420 ± 72.53 microns (p = 0.001), and the mean MV improved from 19.81 ± 2.31mm3 to 9.23 ± 1.38 (p = 0.0001) at the 6-month follow-up.
publishDate 2008
dc.date.none.fl_str_mv 2008
2021
2021
2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/173625
url https://hdl.handle.net/2445/173625
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.2147/opth.s3798
Clinical Ophthalmology, 2008, vol. 2, num. 4, p. 787-791
https://doi.org/10.2147/opth.s3798
dc.rights.none.fl_str_mv cc-by-nc (c) Mesa Gutiérrez, Juan Carlos et al., 2008
http://creativecommons.org/licenses/by-nc/3.0/es
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc-by-nc (c) Mesa Gutiérrez, Juan Carlos et al., 2008
http://creativecommons.org/licenses/by-nc/3.0/es
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 5 p.
application/pdf
dc.publisher.none.fl_str_mv Dove Medical Press
publisher.none.fl_str_mv Dove Medical Press
dc.source.none.fl_str_mv Articles publicats en revistes (Ciències Clíniques)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419306921492480
score 15,812429

Registos relacionados